N-803 Combined With the Broadly Neutralizing Antibodies Plus or Minus haNK Cells for HIV

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
To assess the safety of combination immune therapy in HIV-infected participants whose HIV is controlled with ART, by determining the incidence and severity of adverse events.
Epistemonikos ID: 55720d56ee91ec4b4889b65aa5320a01923a0d20
First added on: May 06, 2024